Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malgorzata Nowicka

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Gigascience|August 29, 2025
SPEX: A modular end-to-end platform for high-plex tissue spatial omics analysisXiao Li, Ximo Pechuan-Jorge, Tyler Risom, et al.
Nature|October 28, 2016
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironmentsEdwin D Hawkins, Delfim Duarte, Olufolake Akinduro, et al.
Blood Advances|July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphomaJonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Blood Advances|July 29, 2021
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatmentMalgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, et al.
Nature|May 6, 2021
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanomaIvana Yen, Frances Shanahan, Jeeyun Lee, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Gigascience|August 29, 2025
SPEX: A modular end-to-end platform for high-plex tissue spatial omics analysisXiao Li, Ximo Pechuan-Jorge, Tyler Risom, et al.
Nature|October 28, 2016
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironmentsEdwin D Hawkins, Delfim Duarte, Olufolake Akinduro, et al.
Blood Advances|July 29, 2021
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphomaJonathan C Strefford, Malgorzata Nowicka, Chantal E Hargreaves, et al.
Blood Advances|July 29, 2021
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatmentMalgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, et al.
Nature|May 6, 2021
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanomaIvana Yen, Frances Shanahan, Jeeyun Lee, et al.
Pageof 3